Maven Securities LTD Makes New $1.67 Million Investment in Sotera Health (NASDAQ:SHC)

Maven Securities LTD bought a new stake in Sotera Health (NASDAQ:SHC) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 100,000 shares of the company’s stock, valued at approximately $1,670,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in SHC. CWM LLC increased its holdings in shares of Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after purchasing an additional 993 shares during the last quarter. True Wealth Design LLC acquired a new position in Sotera Health in the third quarter valued at about $32,000. GAMMA Investing LLC lifted its holdings in shares of Sotera Health by 125.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock worth $50,000 after acquiring an additional 1,660 shares during the period. Point72 DIFC Ltd lifted its stake in Sotera Health by 556.6% during the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after purchasing an additional 5,544 shares during the last quarter. Finally, Capital Performance Advisors LLP acquired a new stake in Sotera Health in the third quarter valued at about $91,000. Institutional investors own 91.03% of the company’s stock.

Sotera Health Price Performance

NASDAQ:SHC opened at $12.83 on Wednesday. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The stock has a fifty day moving average of $15.10 and a 200 day moving average of $14.07. The firm has a market capitalization of $3.63 billion, a price-to-earnings ratio of 51.32 and a beta of 1.96. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The company had revenue of $285.47 million for the quarter, compared to analysts’ expectations of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $0.18 EPS. On average, research analysts expect that Sotera Health will post 0.61 EPS for the current fiscal year.

Insider Activity at Sotera Health

In other news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the sale, the director now directly owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. This trade represents a 16.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 55.12% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Barclays increased their price target on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Citigroup lifted their target price on shares of Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a report on Thursday, November 21st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.50.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.